Investigation into FMC Corporation Securities Fraud Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy FMC?
Source: PRnewswire
- Investigation Launched: Pomerantz LLP is investigating claims against FMC Corporation and its executives regarding potential securities fraud or other unlawful business practices, aiming to protect investor rights and possibly initiate a class action.
- Financial Warning: FMC's revenue guidance for 2026 is set between $3.60 billion and $3.80 billion, reflecting a 5% decline at the midpoint compared to the previous year, while adjusted EBITDA is expected to be between $670 million and $730 million, a 17% drop primarily due to lower prices.
- Stock Price Reaction: Following the financial warning, FMC's stock price fell by $3.32, or 19.54%, closing at $13.67 per share on February 5, 2026, indicating market concerns about the company's outlook.
- Legal Context: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, focusing on advocating for victims of securities fraud and corporate misconduct, having historically recovered multimillion-dollar damages for class members.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FMC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FMC
Wall Street analysts forecast FMC stock price to rise
14 Analyst Rating
3 Buy
10 Hold
1 Sell
Hold
Current: 15.440
Low
13.00
Averages
19.08
High
28.00
Current: 15.440
Low
13.00
Averages
19.08
High
28.00
About FMC
FMC Corporation is a global agricultural sciences company engaged in providing farmers solutions that increase the productivity and resilience of their land. The Company’s crop protection solutions, including biologicals, crop nutrition, digital and precision agriculture, enable growers and crop advisers to address their challenges economically while protecting the environment. Its portfolio consists of three major pesticide categories: insecticides, herbicides and fungicides. The majority of its product lines consist of insecticides and herbicides, and it has a portfolio of fungicides mainly used in high-value crop segments. Its insecticides are used to control a wide spectrum of pests, while its herbicide portfolio primarily targets a large variety of difficult-to-control weeds. In addition, it is also investing in its Plant Health program, which includes biologicals, crop nutrition, and seed treatment products. Biological technologies serve as complements to its synthetic products.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Declining Performance: FMC's revenue fell 5% last year to $3.5 billion, indicating challenges in its core product portfolio, with management expecting another 5% revenue decline this year, putting pressure on the stock price.
- Significant Losses: Under GAAP, FMC reported a loss from continuing operations of $2.2 billion compared to a profit of $403.4 million last year, reflecting financial distress and the impact of restructuring costs.
- Acquisition Potential: Although FMC announced it would explore strategic options, including a potential acquisition, its stock has dropped 68.5% over the past year, currently priced at $13.09, requiring a 15% premium to reach the $15 target.
- Valuation Challenges: FMC's price-to-sales ratio stands at 0.5, down from 1.2 a year ago, suggesting potential value, but management's guidance of declining sales makes the likelihood of the stock reaching $15 seem slim.
See More
- Investigation Launched: Pomerantz LLP is investigating claims against FMC Corporation and its executives regarding potential securities fraud or other unlawful business practices, aiming to protect investor rights and possibly initiate a class action.
- Financial Warning: FMC's revenue guidance for 2026 is set between $3.60 billion and $3.80 billion, reflecting a 5% decline at the midpoint compared to the previous year, while adjusted EBITDA is expected to be between $670 million and $730 million, a 17% drop primarily due to lower prices.
- Stock Price Reaction: Following the financial warning, FMC's stock price fell by $3.32, or 19.54%, closing at $13.67 per share on February 5, 2026, indicating market concerns about the company's outlook.
- Legal Context: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, focusing on advocating for victims of securities fraud and corporate misconduct, having historically recovered multimillion-dollar damages for class members.
See More
- Rare Earth Production Capability: REalloys' Euclid facility is the only site in North America capable of producing heavy rare earth metals and alloys, having secured contracts with the U.S. Department of Defense, Department of Energy, and NASA, solidifying its critical position in defense and industrial markets.
- Integrated Supply Chain Advantage: The company has established a complete supply chain from raw materials to finished magnets by owning the Hoidas Lake rare earth project and securing partnerships across multiple countries, reducing reliance on China and enhancing market competitiveness.
- Technological Innovation and Efficiency: Collaboration with the Saskatchewan Research Council enables REalloys to utilize an AI-driven facility for efficient rare earth metal separation without relying on Chinese technology, with an expected annual output of 525 tonnes of neodymium-praseodymium metal, making it the largest source of heavy rare earth oxides in North America.
- Preparation for Policy Changes: With the implementation of new U.S. defense procurement regulations in 2027, REalloys' production capacity will meet the urgent demand for domestically sourced rare earth metals, ensuring its dominant position in the future market.
See More
- Investigation Launched: Pomerantz LLP is investigating whether FMC Corporation and its executives have engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially initiate a class action lawsuit.
- Financial Warning: In a press release dated February 4, 2026, FMC projected full-year revenue between $3.60 billion and $3.80 billion, reflecting a 5% decline at the midpoint compared to the previous year, while adjusted EBITDA is expected to be between $670 million and $730 million, a 17% drop primarily due to lower prices.
- Stock Price Reaction: Following the financial warning, FMC's stock price fell by $3.32, or 19.54%, closing at $13.67 per share on February 5, 2026, indicating market concerns regarding the company's outlook.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, which could significantly impact FMC's legal liabilities.
See More
- Earnings Release Schedule: FMC Corporation has announced that it will release its Q1 2026 earnings on April 29, 2026, after market close, ensuring timely access to financial information for investors via PR Newswire and the company's website.
- Webcast Timing: The company will host a public webcast conference call on April 30, 2026, at 9:00 a.m. ET, aimed at enhancing transparency and facilitating direct communication with investors.
- Dial-In Information: The conference call offers multiple dial-in options, including local and toll-free numbers for the U.S., ensuring global investor participation and enhancing interaction between the company and its stakeholders.
- Company Overview: FMC is a global agricultural sciences company dedicated to helping growers adapt to environmental changes by providing innovative crop protection solutions, showcasing its commitment and strategic direction in sustainable agriculture.
See More
- Significant Stock Volatility: FMC's stock has plummeted approximately 90% from its 2022 highs, facing heavy debt and patent expirations, yet the market shows disagreement on its future value, with a median analyst price target of $14.00 and a high of $43.00, indicating varied investor perspectives.
- New Product Development Progress: FMC is actively advancing 19 new active ingredients for weed controllers and insecticides, with four products currently in commercial rollout, projected to achieve approximately $200 million in sales by 2025, despite falling short of the $250 million target, reflecting strong market demand with a 54% year-over-year growth.
- Debt Management Commitment: FMC plans to pay down $1 billion in debt through asset sales and licensing agreements by 2026, including the previously announced sale of its Indian commercial business, while continuing its active ingredients manufacturing operations in India, aiming to improve financial health and bolster investor confidence.
- Enhanced Market Competitiveness: Rimisoxafen's
See More











